share_log

佐力药业:百令片拟中选全国中成药采购联盟集采

Zhejiang Jolly Pharmaceutical: Bailin tablets are expected to be selected for the National Chinese Patent Medicine Procurement Alliance.

Breakings ·  Dec 31, 2024 08:10

On December 31, Zhejiang Jolly Pharmaceutical announced that recently, the company and its holding subsidiary Qinghai Zhuo Feng Cordyceps Sinensis Pharmaceutical Co., Ltd. participated in the centralized procurement work of the National Chinese Patent Medicine Procurement Alliance. According to the "Public Announcement of the Proposed Selected Results for Centralized Bulk Procurement of the National Chinese Patent Medicine Procurement Alliance" published by the Hubei Medical Insurance Service Platform on December 30, 2024, Bailin tablets are expected to be selected for this centralized bulk procurement. Bailin tablets are used for the treatment of cough, asthma, lumbar and back pain, and other symptoms caused by deficiency of both lung and kidney, as well as for the auxiliary treatment of chronic bronchitis.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment